drugset / Trial / NCT07322718
Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1, open-label study evaluates the safety, tolerability, and preliminary efficacy of RXIM002, a CD19-targeting circular RNA-mediated in-vivo CAR T-cell therapy, in adults with severe, relapsed, or refractory B cell-mediated autoimmune diseases.
Timeline
- Start
- 2025-12-24
- Primary completion
- 2027-12-19
- Completion
- 2028-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RXIM002 | Other / unclassified | — | Intravenous |
Indications
No indication recorded.